×
About 198 results

ALLMedicine™ Alopecia Totalis Center

Research & Reviews  59 results

Woodhouse-Sakati Syndrome - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/wss/

Jul 7th, 2021 - Virtually all individuals with Woodhouse-Sakati syndrome (WSS) have the endocrine findings of hypogonadism (evident at puberty) and progressive childhood-onset hair thinning that often progresses to alopecia totalis in adulthood. More than half of...

Prediction of the Risk of Alopecia Areata Progressing to Alopecia Totalis and Alopecia ...
https://doi.org/10.1159/000515764
Dermatology (Basel, Switzerland); Zhang T, Nie Y

May 18th, 2021 - Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. Although there is an increased understanding of AA pathogenesis and progress in its treatments, the outcome of AA patients remains unf...

Alopecia areata is not a risk factor for heart diseases: A 10-year retrospective cohort...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104430
PloS One; Lee H, Kim YC et. al.

May 7th, 2021 - Alopecia areata (AA) is an autoimmune skin disease caused by chronic inflammation of hair follicles. Chronic inflammatory skin diseases such as psoriasis and lupus erythematosus can increase the risk of cardiovascular diseases. However, the relati...

Hypotrichosis-lymphedema-telangiectasia syndrome: Report of ileal atresia associated wi...
https://doi.org/10.1002/ajmg.a.62205
American Journal of Medical Genetics. Part A; Coulie R, Niyazov DM et. al.

Apr 14th, 2021 - Hypotrichosis-lymphedema-telangiectasia syndrome (HLTS) is a rare condition caused by pathogenic variants in the SOX18 gene. SOX18 plays a key role in angio- and lymphangiogenesis due to its expression in venous endothelial cells from which the ly...

Alopecia totalis following hand-foot-and-mouth disease.
https://doi.org/10.1111/pde.14550
Pediatric Dermatology; Oska S, Bedford LM et. al.

Mar 2nd, 2021 - We present a case of a 13-month-old male patient with alopecia totalis that began two months after an episode of hand-foot-and-mouth disease. It is hypothesized that the viral infection triggered an autoimmune response, which lead to production of...

see more →

Clinicaltrials.gov  5 results

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
https://clinicaltrials.gov/ct2/show/NCT03315689

Jul 31st, 2019 - This study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution in patients with Alopecia Universalis and Alopecia Totalis. Concentrations of ATI-50002 in the blood and skin will be ...

Alopecia Areata Registry
https://clinicaltrials.gov/ct2/show/NCT00069589

May 13th, 2019 - Alopecia areata is a condition in which hair is lost either from part of the scalp, all of the scalp, or the entire body, and it affects 1% to 2% of the population. It is thought to be an autoimmune disease and in some cases the disease is heredit...

A Study of Secukinumab for the Treatment of Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT02599129

Nov 29th, 2017 - Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body. Alopecia areata is an autoimmune skin disease, which means that the immune system is recognizing ...

Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis
https://clinicaltrials.gov/ct2/show/NCT01314495

Nov 13th, 2012 - Alopecia Areata is a common autoimmune disease, affecting 1% of the general population resulting from autoimmune attack on the hair follicles and usually presents with patchy hair loss. One third of these patients will experience spontaneous remis...

Plaquenil for Alopecia Areata, Alopecia Totalis
https://clinicaltrials.gov/ct2/show/NCT00176982

Aug 12th, 2009 - Alopecia areata is a high prevalence autoimmune disease with significant consequences. Alopecia areata is a tissue restricted autoimmune disease directed at the hair follicle, resulting in hair loss. Patients frequently suffer severe psychiatric c...

see more →

News  15 results

The Case of the Disappearing Eyebrows
https://www.mdedge.com/clinicianreviews/article/195335/dermatology/case-disappearing-eyebrows/page/0/1?channel=203

Feb 28th, 2019 - DISCUSSION This case illustrates several variants of an extremely common condition: alopecia areata (AA), literally translated as “hair loss confined to a particular localized area or areas. ” Although AA is more common in adults, it often affects.

Anthralin shows promise as second-line agent for pediatric alopecia areata
https://www.mdedge.com/pediatrics/article/189807/dermatology/anthralin-shows-promise-second-line-agent-pediatric-alopecia
Jill D. Pivovarov

Nov 29th, 2018 - Given its limited systemic toxicity, topical anthralin is an acceptable second-line treatment option for pediatric alopecia areata (AA), according to Sean Z. Wu, MD, of the department of dermatology, University of Cincinnati, and his associates.

Eczema Drug Dupilumab Spurs Hair Regrowth in Alopecia Totalis
https://www.medscape.com/viewarticle/903234

Oct 9th, 2018 - In addition to effectively treating a resistant case of atopic dermatitis, the eczema drug dupilumab (Dupixent, Regeneron Pharmaceutics) triggered hair growth in a young patient with longstanding alopecia totalis, investigators report. The dual ef...

A new era arrives in alopecia areata therapy
https://www.mdedge.com/dermatology/article/175771/hair-nails/new-era-arrives-alopecia-areata-therapy
Bruce Jancin

Sep 26th, 2018 - PARIS – Each of two oral Janus kinase inhibitors individually showed impressive efficacy and acceptable safety and tolerability for treatment of chronic moderate to severe alopecia areata in a phase 2 study that promises to alter the therapeutic l.

JAK Inhibitors Promising for Alopecia Areata
https://www.medscape.com/viewarticle/902077

Sep 16th, 2018 - PARIS — Two investigational oral Janus kinase (JAK) inhibitors are safe and effective for patients with moderate to severe hair loss, according to 24-week interim findings from a randomized, double-blind, placebo-controlled, multicenter phase 2 tr...

see more →